ReviewDer Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft2003
[Immunomodulation in penetrating keratoplasty. Current status and perspectives].
Review in Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 16 citations in OpenAlex.
- [Ranking of systemic steroids after normal-risk keratoplasty. Results of a randomized prospective study].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2005Trial
- Adverse effects of low-dose systemic cyclosporine therapy in high-risk penetrating keratoplasty.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2015Article
- [Immunosuppressives to prevent rejection reactions after allogeneic corneal transplantation].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2014Review
- Outcome of penetrating keratoplasty in corneal ulcer: a single-center experience.Clinical ophthalmology (Auckland, N.Z.) · 2011Article
- [Intracameral application of corticosteroids for treating severe endothelial rejection after penetrating keratoplasty].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2007Article
- [Immune suppression following perforating keratoplasty].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2007Review
- Tacrolimus immunosuppression in high-risk corneal grafts.The British journal of ophthalmology · 2007Article
- [Classification of biomedical research reports as a reference for evidence-based medicine in ophthalmology. A survey considering as example the journal Der Ophthalmologe].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The immune privileged nature of the cornea contributes to the favourable outcome in corneal grafts. However, preventive measures are necessary to reduce allograft rejection particular in "high-risk" cases. Although corticosteroids are still a major component of our immunopharmacological armentarium, they might be supplemented by other more specific immunomodulating agents. The spectrum includes agents such as azathioprin, methotrexate or more specific calcineurin inhibitors affecting T-cells (cyclosporin A, FK506) and highly selective monoclonal antibodies directed against T-cell subpopulations and other targets. In order to better evaluate the risks and benefit of these agents, the properties of established and forthcoming agents are presented. In addition, this review attempts to address some new concepts of tolerance induction following penetrating keratoplasty.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.